Kazia Therapeutics Annual Report 2021

Average age at diagnosis with DIPG 5-7 years Number of new diagnoses of brain metastases each year in United States >200,000 Five-year survival rate of primary CNS lymphoma 30% SOURCE: American Association of Neurological Surgeons Green & Hogg (2020) SOURCE: DIPG.org Phase I study of EVT801 expected to commence by end CY2021 96 Up to 96 patients planned in EVT801 phase I study Overall Survival Paxalisib 17.5 months Temozolomide (existing standard of care) 12.7 months Interim analysis as at November 2020 as at 30 June 2021 Kazia Therapeutics is an innovative oncology-focused drug development company. We collaborate with clinicians, scientists, and researchers around the world to bring new hope to patients with cancer. Enterprise value (market capitalisation, less cash) (AU$) Indicative Analyst Valuation (AU$) SOURCE: Edison Research 30 June 2021 30 June 2016 30 June 2017 30 June 2018 30 June 2019 30 June 2020 $3.8m $5.7m $12.7m $14.9m $146.0m $35.6m 2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 3 $103m $115m $346m $244m $145m $137m 19 Sept 2018 01 Apr 2019 23 Jun 2019 28 Aug 2020 10 Dec 2020 19 Apr 2021